Samuel Waksal
About Samuel Waksal
Samuel Waksal is a prominent figure in biotechnology, serving as the Founder and Founding Chairman of MeiraGTx and the Chief Executive Officer of Graviton Bioscience. With a background in academic medicine, he has contributed to the development of significant cancer therapies, including Cyramza and Erbitux.
Work at MeiraGTx
Samuel Waksal serves as the Founder and Founding Chairman of MeiraGTx, a position he has held since 2015. Under his leadership, the company has focused on developing innovative gene therapies to address unmet medical needs. His role involves strategic oversight and guiding the company's vision in the biotechnology sector. MeiraGTx operates in the Greater New York City Area and London, England, contributing to advancements in genetic medicine.
Current Role at Graviton Bioscience
Since 2022, Samuel Waksal has been the Chief Executive Officer of Graviton Bioscience, located in New York, United States. In this role, he leads the company's efforts in biotechnology and drug development, leveraging his extensive background in academic medicine. His leadership aims to drive innovation and foster the development of new therapeutic solutions.
Visiting Fellow at BRAIN-MIND INSTITUTE
Samuel Waksal has been a Visiting Fellow at the BRAIN-MIND INSTITUTE since 2018, collaborating with Weill Cornell Medicine. His work involves contributing to research initiatives and sharing his expertise in biotechnology and drug development. This position allows him to engage with the academic community and stay at the forefront of scientific advancements.
Education and Expertise
Samuel Waksal studied at The Ohio State University College of Medicine, where he focused on Immunology and earned his Doctorate. His academic background in medicine has significantly contributed to his expertise in biotechnology and drug development, enabling him to lead various initiatives in the pharmaceutical industry.
Achievements in Drug Development
Samuel Waksal has played a pivotal role in the development of several significant cancer therapies. He developed Cyramza, a drug for treating various cancers, including gastric and lung cancer. Additionally, he was involved in the creation of Erbitux, which is used for colorectal and head and neck cancers. Furthermore, he founded Kadmon Biopharmaceuticals, focusing on innovative therapies for unmet medical needs.